Total Payments
$1.2M
2024 Payments
$127,708
Companies
103
Transactions
4,156
Medicare Patients
15,713
Medicare Billing
$2.8M
Payment Breakdown by Category
Other$912,283 (75.6%)
Consulting$116,274 (9.6%)
Travel$88,443 (7.3%)
Food & Beverage$87,003 (7.2%)
Gifts$2,232 (0.2%)
Education$1,009 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $753,465 | 416 | 62.4% |
| Honoraria | $158,450 | 61 | 13.1% |
| Consulting Fee | $116,274 | 89 | 9.6% |
| Travel and Lodging | $88,443 | 223 | 7.3% |
| Food and Beverage | $87,003 | 3,327 | 7.2% |
| Gift | $2,232 | 1 | 0.2% |
| Education | $1,009 | 28 | 0.1% |
| Entertainment | $280.48 | 1 | 0.0% |
| Grant | $87.90 | 2 | 0.0% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$1.2M
4,148 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $165,844 | 440 | $0 (2024) |
| Biogen, Inc. | $131,976 | 478 | $0 (2024) |
| SK Life Science, Inc. | $113,255 | 223 | $0 (2024) |
| Amgen Inc. | $106,211 | 184 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $99,237 | 83 | $0 (2024) |
| Lundbeck LLC | $92,738 | 287 | $0 (2024) |
| ABBVIE INC. | $52,699 | 161 | $0 (2024) |
| Lilly USA, LLC | $44,813 | 123 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $42,120 | 82 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $40,524 | 125 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $127,708 | 462 | E.R. Squibb & Sons, L.L.C. ($27,843) |
| 2023 | $122,866 | 431 | SK Life Science, Inc. ($25,525) |
| 2022 | $159,718 | 502 | E.R. Squibb & Sons, L.L.C. ($43,991) |
| 2021 | $191,712 | 574 | Biohaven Pharmaceuticals, Inc. ($36,711) |
| 2020 | $158,701 | 469 | SK Life Science, Inc. ($28,926) |
| 2019 | $154,918 | 530 | Teva Pharmaceuticals USA, Inc. ($36,951) |
| 2018 | $137,283 | 590 | Teva Pharmaceuticals USA, Inc. ($41,129) |
| 2017 | $154,338 | 598 | Teva Pharmaceuticals USA, Inc. ($34,838) |
All Payment Transactions
4,156 individual payment records from CMS Open Payments — Page 1 of 167
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Neuroscience | ||||||
| 12/20/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Neurology | ||||||
| 12/20/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.07 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Neurology | ||||||
| 12/17/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $20.31 | General |
| 12/13/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $2.14 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/12/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $24.22 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Neurology | ||||||
| 12/10/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: PAIN | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,620.00 | General |
| Category: Neuroscience | ||||||
| 12/09/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $25.16 | General |
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $26.54 | General |
| Category: Neuroscience | ||||||
| 12/05/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $12.89 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Consulting Fee | Cash or cash equivalent | $105.00 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Consulting Fee | Cash or cash equivalent | $50.25 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Consulting Fee | Cash or cash equivalent | $50.25 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 4,142 | 5,927 | $3.5M | $699,361 |
| 2022 | 27 | 3,680 | 5,523 | $3.2M | $664,947 |
| 2021 | 30 | 3,858 | 6,013 | $3.4M | $739,448 |
| 2020 | 33 | 4,033 | 6,602 | $3.4M | $723,462 |
Total Patients
15,713
Total Services
24,065
Medicare Billing
$2.8M
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 266 | 267 | $534,000 | $114,909 | 21.5% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 243 | 243 | $486,000 | $109,468 | 22.5% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 295 | 300 | $240,000 | $92,929 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 467 | 607 | $181,908 | $44,079 | 24.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 284 | 597 | $298,500 | $42,000 | 14.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 334 | 334 | $100,200 | $38,745 | 38.7% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 198 | 198 | $158,400 | $38,033 | 24.0% |
| 70551 | Mri scan of brain without contrast | Office | 2023 | 243 | 255 | $382,500 | $36,827 | 9.6% |
| 64445 | Injection of anesthetic agent and/or steroid into lower back and leg nerve (sciatic nerve) | Office | 2023 | 141 | 197 | $185,501 | $32,098 | 17.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 186 | 186 | $93,000 | $22,638 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 308 | 318 | $63,600 | $19,199 | 30.2% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2023 | 125 | 127 | $190,500 | $18,039 | 9.5% |
| 95805 | Sleep study, multiple trials | Office | 2023 | 49 | 49 | $73,500 | $14,683 | 20.0% |
| 95908 | Nerve conduction, 3-4 studies | Office | 2023 | 181 | 182 | $72,800 | $14,322 | 19.7% |
| 64415 | Injection of anesthetic agent and/or steroid into arm nerve bundle (brachial plexus) | Office | 2023 | 75 | 105 | $96,500 | $14,307 | 14.8% |
| 72141 | Mri scan of upper spinal canal without contrast | Office | 2023 | 94 | 95 | $142,500 | $12,995 | 9.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 120 | 120 | $72,000 | $10,846 | 15.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 51 | $20,400 | $6,022 | 29.5% |
| 73221 | Mri scan of arm joint without contrast | Office | 2023 | 24 | 29 | $43,500 | $4,435 | 10.2% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 25 | 25 | $12,500 | $3,256 | 26.0% |
| 72195 | Mri scan of pelvis without contrast | Office | 2023 | 16 | 17 | $25,500 | $2,874 | 11.3% |
| 72146 | Mri scan of middle spinal canal without contrast | Office | 2023 | 13 | 15 | $22,500 | $2,164 | 9.6% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 188 | 344 | $8,600 | $2,051 | 23.8% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 22 | 22 | $3,058 | $1,073 | 35.1% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 14 | 22 | $3,300 | $841.50 | 25.5% |
About Dr. Lance Kim, DO
Dr. Lance Kim, DO is a Vascular Neurology healthcare provider based in Ocala, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366411514.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Kim, DO has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $127,708 received in 2024. These payments were reported across 4,156 transactions from 103 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($753,465).
As a Medicare-enrolled provider, Kim has provided services to 15,713 Medicare beneficiaries, totaling 24,065 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Vascular Neurology
- Other Specialties Neurology, Pain Medicine
- Location Ocala, FL
- Active Since 03/17/2006
- Last Updated 01/23/2025
- Taxonomy Code 2084V0102X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1366411514
Products in Payments
- ZEPOSIA (Drug) $123,942
- XCOPRI (Drug) $89,060
- Aimovig (Biological) $85,767
- VYEPTI (Biological) $74,853
- NURTEC ODT (Drug) $61,905
- AUSTEDO (Drug) $58,661
- TECFIDERA (Drug) $51,766
- UBRELVY (Drug) $48,247
- COPAXONE (Drug) $42,429
- APTIOM (Drug) $38,490
- TYSABRI (Biological) $36,333
- AJOVY (Biological) $29,154
- Trudhesa (Drug) $27,563
- ACTHAR (Biological) $26,041
- AJOVY (Drug) $24,116
- NUPLAZID (Drug) $23,290
- Adlarity (Drug) $22,925
- Cenobamate (Drug) $21,421
- Fycompa (Drug) $21,069
- QULIPTA (Drug) $21,048
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.